IRIS
AURIEMMA, RENATA SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.639
EU - Europa 2.776
NA - Nord America 2.750
SA - Sud America 554
AF - Africa 94
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.822
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.614
SG - Singapore 1.947
RU - Federazione Russa 1.488
CN - Cina 845
BR - Brasile 436
HK - Hong Kong 349
IT - Italia 322
VN - Vietnam 264
DE - Germania 211
SE - Svezia 152
FI - Finlandia 135
NL - Olanda 109
CA - Canada 76
GB - Regno Unito 71
IE - Irlanda 71
UA - Ucraina 62
AR - Argentina 58
FR - Francia 49
IN - India 47
MX - Messico 36
BD - Bangladesh 34
KR - Corea 29
CI - Costa d'Avorio 25
ZA - Sudafrica 24
EC - Ecuador 22
PL - Polonia 21
ES - Italia 18
IQ - Iraq 16
AT - Austria 14
TR - Turchia 14
IR - Iran 13
ID - Indonesia 12
KE - Kenya 10
LT - Lituania 10
CO - Colombia 9
JP - Giappone 9
BE - Belgio 8
VE - Venezuela 8
CZ - Repubblica Ceca 7
IL - Israele 7
MA - Marocco 7
PK - Pakistan 7
PY - Paraguay 7
UZ - Uzbekistan 7
EG - Egitto 6
AE - Emirati Arabi Uniti 5
UY - Uruguay 5
CH - Svizzera 4
CL - Cile 4
DO - Repubblica Dominicana 4
LB - Libano 4
OM - Oman 4
PT - Portogallo 4
AL - Albania 3
DZ - Algeria 3
JM - Giamaica 3
JO - Giordania 3
PA - Panama 3
PE - Perù 3
SA - Arabia Saudita 3
TN - Tunisia 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
EE - Estonia 2
GA - Gabon 2
GM - Gambi 2
GT - Guatemala 2
HN - Honduras 2
LC - Santa Lucia 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
PF - Polinesia Francese 2
RO - Romania 2
RW - Ruanda 2
SN - Senegal 2
TH - Thailandia 2
TL - Timor Orientale 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GH - Ghana 1
GP - Guadalupe 1
GR - Grecia 1
HT - Haiti 1
Totale 9.804
Salva come PNG Salva come JPEG
Città #
Singapore 881
Moscow 378
Chandler 366
Hong Kong 349
Beijing 257
Ashburn 226
Hefei 165
Santa Clara 137
Naples 109
Munich 103
Millbury 97
Ho Chi Minh City 95
Amsterdam 92
Los Angeles 82
Princeton 71
Jacksonville 70
Nanjing 58
Hanoi 55
Boston 52
Wilmington 51
The Dalles 47
Redondo Beach 43
São Paulo 41
Buffalo 40
Helsinki 37
New York 37
Napoli 36
Ottawa 36
Seattle 36
Woodbridge 32
Turku 31
Dallas 29
Des Moines 27
Seoul 27
Houston 23
Falls Church 21
Falkenstein 19
Hebei 19
Mexico City 18
Montreal 18
Warsaw 18
Nanchang 16
Orem 16
Phoenix 16
San Francisco 16
Frankfurt am Main 15
Rome 15
Shenyang 15
Chicago 14
Lawrence 14
Stockholm 14
Toronto 14
Denver 13
Nuremberg 13
Rio de Janeiro 13
Dublin 12
Haiphong 12
Ann Arbor 11
Ardabil 11
Jiaxing 11
Johannesburg 11
Quito 11
Boydton 10
Changsha 10
Curitiba 10
Da Nang 10
Nairobi 10
Ankara 9
Kronberg 9
Manchester 9
Poplar 9
Porto Alegre 9
San Mateo 9
Shanghai 9
Tianjin 9
Atlanta 8
Augusta 8
Boardman 8
Bologna 8
Brooklyn 8
Dhaka 8
London 8
Salvador 8
Tokyo 8
Charlotte 7
Kochi 7
Mumbai 7
Norwalk 7
Afragola 6
Baghdad 6
Belo Horizonte 6
Brasília 6
Brussels 6
Buenos Aires 6
Chennai 6
Guangzhou 6
Hastings 6
Hải Dương 6
Joinville 6
Ninh Bình 6
Totale 4.906
Salva come PNG Salva come JPEG
Nome #
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 148
The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study 131
Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome 127
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 127
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 126
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 120
Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial 120
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group 119
Bisphenol A: An emerging threat to female fertility 119
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 118
New perspectives in the medical treatment of acromegaly 118
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 118
Adverse events associated with somatostatin analogs in acromegaly. 116
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 116
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 115
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 115
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 115
Hypertension in acromegaly and in the normal population: prevalence and determinants 114
Impact of Somatostatin Analogs vs. Surgery on glucose metabolism in acromegaly: Results of a 5 years observational, open, prospective study 112
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 111
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 110
Fertility in Acromegaly: a single center experience on female patients during active disease and after disease remission 109
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 107
Acromegaly and the cardiovascular system 106
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. 106
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma 106
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 104
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas 104
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 103
Effect of Cabergoline on Metabolism in Prolactinomas. 103
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 103
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 103
Approach to the Patient with Prolactinoma 102
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 102
The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life 102
Mediterranean Diet: What Are the Consequences for Menopause? 101
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. 101
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. 100
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 98
Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center 97
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study 96
Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study 96
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 96
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 96
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 96
Somatostatin analogs in the clinical management of pituitary neoplasms 95
Investigational drugs for the treatment of acromegaly: new agents to transform therapy 94
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study 94
Effect of the acute administration of the Dopamine Agonist Cabergoline on glucose tolerance and Insuline Sensitivity in patient with obesity. 92
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. 90
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 90
Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements 90
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment 90
The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer 89
Severe systemic complications of acromegaly 89
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs 88
Cardiometabolic effects of hypoprolactinemia 87
Erratum to: Pituitary tumors and pregnancy: The interplay between a pathologic condition and a physiologic status (Journal of Endocrinological Investigation (2014) 37, (99-112) DOI: 10.1007/s40618-013-0019-8) 87
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms 87
Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity? 86
Prolactin effects on the pathogenesis of diabetes mellitus 86
Metabolic effects of prolactin 86
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). 85
Efficacy and tolerability of treatment with pegvisomant in acromegaly: An overview of literature 85
Hyperprolactinemia after menopause: Diagnosis and management 84
Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health 84
Medical consequences of acromegaly: what are the effects of biochemical control? 83
Acromegaly and changes in growth parameters: A focus on cardiovascular,metabolic, respiratory abnormalities, malignancies, and bone alterations 83
Risk Assessment of Diabetes Mellitus during and after Pregnancy in Women with Prolactinomas 81
The safety of treatments for prolactinomas 81
Prevalence of the Metabolic Syndrome in moderately-severely obese subjects with and without Growth Hormone Deficiency. 81
The role of somatostatin receptors in the medical treatment of acromegaly 80
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly 80
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy 78
TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON CARDIAC ARRHYTHMIAS. 78
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance 77
Pituitary carcinomas. 76
Diabetes mellitus, vaginal microbiome and sexual function: Outcomes in postmenopausal women 75
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 75
Treatment with GH receptor antagonist in acromegaly:effect on cardiac arrhythmias. 75
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. 75
Glucose abnormalities associated to prolactin secreting pituitary adenomas 73
Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience 72
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 72
Effects of the metabolic syndrome (METS) on gonadal function and sperm parameters in acromegalic patients: a retrospective analisys 72
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without chiasmal compression. 69
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities 69
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas 69
PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma 68
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 68
Different effect of acute administration of the dopamine agonist cabergoline on glucose tolerance and insulin sensitivity in obese pateints in relation to GH status. 67
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. 65
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-monthstudy. 64
Cabergoline use for pituitary tumors and valvular disorders. 64
Dopamine Agonists: From the 1970s to Today 64
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. 63
Probiotics and Prebiotics: Any Role in Menopause-Related Diseases? 62
Clinical Case 1 61
Cushing, acromegaly, GH deficiency and tendons 59
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly 50
Totale 9.239
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.921
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.921
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021170 0 0 0 0 0 50 13 3 28 11 60 5
2021/2022571 10 0 0 3 16 79 12 19 83 35 113 201
2022/2023813 96 88 20 66 96 89 4 69 144 98 34 9
2023/2024509 22 87 60 54 26 40 13 61 9 10 75 52
2024/20253.266 163 157 43 30 79 175 407 216 171 257 1.263 305
2025/20263.989 717 541 727 585 1.203 216 0 0 0 0 0 0
Totale 10.002